Name, year | Diagnosis in study population | Design | Consecutive | n(eyes) | Mean age (years) | Female population | Patient selection | Index test | Reference standard | Flow and timing |
---|---|---|---|---|---|---|---|---|---|---|
Han-Hwa Hu, 1993 [10] | CIS <50%: n = 84; CIS 50–74%: n = 23; CIS 75–99%: n = 17; CIS 100%: n = 8 | Cross sectional study | n.r. | 132 | 63 | 11% | 2 | 2 | 1 | 1 |
Paivansalo,1999 [11] | both side CIS <80%: n = 46 ; at least one side CIS >80%:n = 48 | Cross sectional study | n.r. | 94 | 63.1 | 38% | 2 | 2 | 1 | 1 |
Arai, 1998 [12] | DM without DRP: n = 27, DRP: n = 25 | Cross sectional study | n.r. | 52 | DM without DRP: 50.0, DRP: 56.1 | 45% | 1 | 2 | 1 | 3 |
Basturk, 2012 [13] | DM II without DRP: n = 40, DRP: n = 51, healthy subjects: n = 27 | Cross sectional study | yes | 118 | DRP: 55.88, DM without DRP: 53.25, healthy subjects 53.59 | DM without DRP: 45%, DRP: 49%; healthy controls: 48% | 1 | 2 | 1 | 3 |
Jimenez-Aragon, 2013 [14] | Early glaucoma no-progression group: n = 59; early glaucoma progression group: n = 12 | Longitudinal and prospective study | yes | 71 | No progression group 54.03, Progression group 55.75 | No-Progression group: 59%; Progression group: 75% | 1 | 1 | 1 | 3 |
Arsène, 2002 [18] | CRVO-ischaemic: n = 18; CRVO-non-ischaemic: n = 51; BRVO (ischaemic and non-ischaemic):n = 33 | Longitudinal and prospective study | n.r. | 102 | 61 | 38% | 2 | 1 | 1 | 2 |
Tranquart, 1999 [19] | CRVO-ischemic: n = 18; CRVO: non-ischaemic: n = 51 | Cross sectional study | n.r. | 69 | 61 (based on 102 subjects) | 38% (based on 102 subjects) | 2 | 1 | 1 | 3 |
Plange, 1999 [17] | NTG: n = 62; healthy controls: n = 40 | Cross-sectional study | yes | 102 | NTG: 57, healthy subjects: 58 | 37% | 1 | 1 | 1 | 1 |
Martinez, 2005 [15] | POAG progression group: n = 23; POAG no-progression group: n = 26 | Prospective cohort study | yes | 49 | 63.7 | 53% | 1 | 3 | 1 | 1 |
Suprasanna, 2014 [16] | POAG-progression group: n = 25; POAG no-progression-group: n = 53 | Case control study | n.r. | 78 | 62.6 | 41% | 2 | 2 | 1 | 1 |
Williamson, 1994 [6] | CRVO without iris neovascularization: n = 22, CRVO with iris neovascularization: n = 8 | Prospective cohort study | n.r. | 30 | 67.2 (based on 80 patients) | 49% (based on 80 subjects) | 1 | 2 | 1 | 2 |